Literature DB >> 25385945

Are you ready for more insulin concentrations?

Alissa R Segal1, Nuha El Sayed2.   

Abstract

Practitioners need to prepare for a rapid expansion of new concentrated insulins. For many years, the treatment regimens for patients have been limited to 2 concentrations (100 units/mL and 500 units/mL), which pose challenges to both patients and providers. As the new concentrated insulins are at various stages of development, this manuscript reviews the available information on the new concentrated products. This information was obtained from publications, poster presentations, abstracts, and the manufacturers for the products in earlier stages of development. To have a basis for comparison, it is important to understand the activity profile and the challenges with use of the currently available concentrated insulin, regular insulin 500 units/mL (U500R). We also examine how the newer products may assist clinicians and patients with the difficulties faced with the use of U500R.
© 2014 Diabetes Technology Society.

Entities:  

Keywords:  U-200 degludec insulin; U-300 glargine insulin; U-500 regular insulin; concentrated insulin therapy; subcutaneous injection

Mesh:

Substances:

Year:  2014        PMID: 25385945      PMCID: PMC4604590          DOI: 10.1177/1932296814557860

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  31 in total

1.  Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Authors:  T Heise; L Nosek; S G Bøttcher; H Hastrup; H Haahr
Journal:  Diabetes Obes Metab       Date:  2012-07-10       Impact factor: 6.577

2.  Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

Authors:  T Heise; L Hermanski; L Nosek; A Feldman; S Rasmussen; H Haahr
Journal:  Diabetes Obes Metab       Date:  2012-06-07       Impact factor: 6.577

Review 3.  The use of U-500 in patients with extreme insulin resistance.

Authors:  Elaine Cochran; Carla Musso; Phillip Gorden
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

Review 4.  Clinical use of U-500 regular insulin: review and meta-analysis.

Authors:  Sirimon Reutrakul; Kristen Wroblewski; Rebecca L Brown
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

5.  Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance.

Authors:  Wendy S Lane
Journal:  Endocr Pract       Date:  2006 May-Jun       Impact factor: 3.443

Review 6.  Use of concentrated insulin human regular (U-500) for patients with diabetes.

Authors:  Alissa R Segal; Jack E Brunner; F Taylor Burch; Jeffrey A Jackson
Journal:  Am J Health Syst Pharm       Date:  2010-09-15       Impact factor: 2.637

7.  Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient.

Authors:  Betul Hatipoglu; Sonia Soni; Valerie Espinosa
Journal:  Endocr Pract       Date:  2006 Sep-Oct       Impact factor: 3.443

8.  Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes.

Authors:  Deepti G Bulchandani; Tara Konrady; Mitchell S Hamburg
Journal:  Endocr Pract       Date:  2007 Nov-Dec       Impact factor: 3.443

9.  Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.

Authors:  R R Henry; B Gumbiner; T Ditzler; P Wallace; R Lyon; H S Glauber
Journal:  Diabetes Care       Date:  1993-01       Impact factor: 19.112

10.  Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.

Authors:  Amparo de la Peña; Matthew Riddle; Linda A Morrow; Honghua H Jiang; Helle Linnebjerg; Adam Scott; Khin M Win; Marcus Hompesch; Kenneth F Mace; Jennie G Jacobson; Jeffrey A Jackson
Journal:  Diabetes Care       Date:  2011-10-12       Impact factor: 19.112

View more
  9 in total

1.  Challenges in Delivering Smaller Doses of Insulin.

Authors:  Brigitte I Frohnert; G Todd Alonso
Journal:  Diabetes Technol Ther       Date:  2015-09       Impact factor: 6.118

2.  Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.

Authors:  Tao Wang; Kenneth A Conrad; Kate van Brunt; Tina M Rees
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

Review 3.  Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.

Authors:  Rebecca Schechter; Sirimon Reutrakul
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

Review 4.  Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.

Authors:  Jeremy L Johnson; Jessica M Downes; Cassandra K Obi; Nana B Asante
Journal:  J Diabetes Sci Technol       Date:  2016-11-28

5.  Effect of Poly(trehalose methacrylate) Molecular Weight and Concentration on the Stability and Viscosity of Insulin.

Authors:  Madeline B Gelb; Heather D Maynard
Journal:  Macromol Mater Eng       Date:  2021-05-22       Impact factor: 4.402

6.  Compensation of Strong Water Absorption in Infrared Spectroscopy Reveals the Secondary Structure of Proteins in Dilute Solutions.

Authors:  Bonghwan Chon; Shuyu Xu; Young Jong Lee
Journal:  Anal Chem       Date:  2021-01-12       Impact factor: 6.986

Review 7.  Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes.

Authors:  Claudio Maffeis; Ivana Rabbone
Journal:  Paediatr Drugs       Date:  2022-07-26       Impact factor: 3.930

Review 8.  Concentrated insulins: the new basal insulins.

Authors:  Elizabeth M Lamos; Lisa M Younk; Stephen N Davis
Journal:  Ther Clin Risk Manag       Date:  2016-03-09       Impact factor: 2.423

9.  Challenges With Insulin in the Inpatient Setting.

Authors:  Denise M Kolanczyk; Rachel C Dobersztyn
Journal:  Diabetes Spectr       Date:  2016-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.